Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1.02 USD | +1.99% | +5.15% | +47.40% |
Kurzporträt
Mitarbeiterzahl: 28
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
John Celebi
CEO | Chief Executive Officer | 52 | 01.02.18 |
Erin Colgan
DFI | Director of Finance/CFO | 43 | 01.07.20 |
Chief Tech/Sci/R&D Officer | 51 | 01.09.19 | |
Alice Drumheller
CTO | Chief Tech/Sci/R&D Officer | - | 01.08.18 |
Michael Biega
IRC | Investor Relations Contact | - | 01.06.22 |
Stephanie Krebs
PRN | Corporate Officer/Principal | - | 01.11. |
General Counsel | - | 01.07.22 | |
Bao Le
LAW | General Counsel | - | 01.06.21 |
Corporate Officer/Principal | 44 | 01.06.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
William Ringo
CHM | Chairman | 78 | 08.03.22 |
John Celebi
CEO | Chief Executive Officer | 52 | 01.02.18 |
Bob Holmen
BRD | Director/Board Member | 60 | 01.01.17 |
Thomas Ricks
BRD | Director/Board Member | 70 | 01.01.15 |
Deneen Vojta
BRD | Director/Board Member | 59 | 29.01.20 |
James Peyer
BRD | Director/Board Member | 37 | 01.01.20 |
Kristian Humer
BRD | Director/Board Member | 49 | 30.07.21 |
Jessie English
BRD | Director/Board Member | 60 | 01.04.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 25 070 980 | 16 384 834 ( 65,35 %) | 0 | 65,35 % |
Unternehmenskontakt
Sensei Biotherapeutics, Inc.
1405 Research Boulevard` Suite 125
20850, Rockville
+240 243 8000
http://senseibio.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+47.40% | 25.57 Mio. | |
-2.31% | 103 Mrd. | |
+0.56% | 95.28 Mrd. | |
+1.69% | 22.15 Mrd. | |
-17.37% | 21.02 Mrd. | |
-9.30% | 18.15 Mrd. | |
-41.01% | 16.74 Mrd. | |
-14.85% | 16.05 Mrd. | |
+3.21% | 13.68 Mrd. | |
+33.54% | 12.17 Mrd. |
- Börse
- Aktien
- A2QM6J Aktie
- Unternehmen Sensei Biotherapeutics, Inc.